Phenotypes associated with this allele

• Allele Symbol: Lhx3^tm1(cre)Slp
• Allele Name: targeted mutation 1, Samuel L Pfaff
• Allele ID: MGI:3513299
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Lhx3^tm1(cre)Slp/Lhx3^tm1(cre)Slp	involves: 129S1/Sv	MGI:3717901
cn2	Gt(ROSA)26Sor^tm1(tTA)Roos/? Lhx3^tm1(cre)Slp/Lhx3^+ Tg(tetO-SOD1,-luc)1Roos/0	involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6	MGI:3806327
cn3	Gt(ROSA)26Sor^tm1(tTA)Roos/? Lhx3^tm1(cre)Slp/Lhx3^+ Tg(tetO-SOD1*G93A,-luc)1Roos/0	involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6	MGI:3806328

Genotype
MGI:3717901

hm1

• Allelic Composition: Lhx3^tm1(cre)Slp/Lhx3^tm1(cre)Slp
• Genetic Background: involves: 129S1/Sv

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

abnormal Rathke's pouch apoptosis ( J:119270 )

• at E11.5 and E12.5 increased numbers of apoptotic cells are seen in the ventral portion of the pouch

abnormal Rathke's pouch development ( J:119270 )

• while normal in size at E11.5, by E12.5 Rathke's pouch fails to expand or develop further

• at E12.5 expression analysis indicates absence of early differentiated pituitary cells

absent adenohypophysis ( J:119270 )

• largely missing at E15.5

• however, the posterior lobe appears normal

small pituitary intermediate lobe ( J:119270 )

• reduced in size at E15.5

nervous system

abnormal Rathke's pouch apoptosis ( J:119270 )

• at E11.5 and E12.5 increased numbers of apoptotic cells are seen in the ventral portion of the pouch

abnormal Rathke's pouch development ( J:119270 )

• while normal in size at E11.5, by E12.5 Rathke's pouch fails to expand or develop further

• at E12.5 expression analysis indicates absence of early differentiated pituitary cells

absent adenohypophysis ( J:119270 )

• largely missing at E15.5

• however, the posterior lobe appears normal

small pituitary intermediate lobe ( J:119270 )

• reduced in size at E15.5

Genotype
MGI:3806327

cn2

• Allelic Composition: Gt(ROSA)26Sor^tm1(tTA)Roos/?; Lhx3^tm1(cre)Slp/Lhx3⁺; Tg(tetO-SOD1,-luc)1Roos/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6

nervous system

nervous system phenotype ( J:138761 )

N • mice show no significant differences from triple mutants carrying the G93A version of SOD1, in the rotarod test when tested at 300 days and later

growth/size/body

growth/size/body region phenotype ( J:138761 )

N • body weight is similar to non-transgenic controls

Genotype
MGI:3806328

cn3

• Allelic Composition: Gt(ROSA)26Sor^tm1(tTA)Roos/?; Lhx3^tm1(cre)Slp/Lhx3⁺; Tg(tetO-SOD1*G93A,-luc)1Roos/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6

nervous system

nervous system phenotype ( J:138761 )

N • mice show no significant differences relative to triple mutants carrying wild-type human SOD1, in the rotarod test when tested at 300 days and later

decreased motor neuron number ( J:138761 )

• significant decrease in number of spinal motor neurons (MNs) compared to wild-type and transgenic controls is observed at 450 days of age

abnormal ventral spinal root morphology ( J:138761 )

• significant decrease in number of axons in L5 anterior root at 450 days is observed compared to triple mutants expressing wild-type human SOD1

growth/size/body

decreased body weight ( J:138761 )

• after 300 days, mean body weight is reduced relative to wild-type or to triple mutants carrying the wild-type human SOD1 gene